Pharma Focus Asia Magazine

Issue 18 | 2013

Issue 18


Pharma Partnerships

The changing model

Crossindustry partnerships have changed the way pharmaceutical companies approach drug research and manufacturing Factors such as expiring patents paucity of blockbuster drugs need for cost cutting and more targeted cures has forced pharma companies ..


Reducing Uncertainty, Increasing Confidence


New FIPNET Paradigm

Powered by technology and innovation

The drive for industry transformation in the shadow of blockbuster drug patent expirations has fundamentally changed industry best practices as companies have pursued increased operational efficiency agility and accelerated RD Technological innovatio..

The Role of ICH-E5

Enhancing product value and accelerating global drug development

ICHE5 was established largely in response to a drug approval lag in Japan relative to the US and Europe The main goal of the Guidance was to eliminate the need to duplicate full clinical development programs in various regions of the world However th..

On the Partnering Path from the US to Asia

How far, how fast for university-industry collaborations?

In the US the expansion of partnerships was a natural outgrowth of the historical trends of biotech spinoffs arising from university labs and researchers at academic medical centers already being engaged in industrysponsored drug and device clinical ..

CHINA-PHARM 2013 Back to Shanghai

Opportunities lie ahead for the pharmaceutical industry


Strategic Partnerships and External Innovation

Partnerships and collaborations to create external innovation are an increasing part of the industry landscape This article highlights some examples of emerging trends in partnership and outlines key areas that can impact performance We propose that ..

Nanonization of Active Pharmaceutical Ingredients


Success Factors for a Strong Drug Development Partnership

Successful partnerships require a commitment to change and a reevaluation of core competencies across both organisations Through the application of a clear strategy committed leadership and a high degree of flexibility strong and sustainable sponsorC..

Innovative Partnership Model

Translating research into products and best practices for spinal cord injury

The Rick Hansen Institute RHI is a Canadabased notforprofit organisation committed to accelerating the translation of discoveries and best practices into improved treatments for people with spinal cord injuries SCI RHI is developing innovative partne..

Open Innovative Partnerships

A working model for the future of drug discovery and development

Although investment in pharmaceutical research and development has increased substantially in the last decade the lack of a corresponding output in terms of new approved drugs indicates that therapeutic innovation has become extremely challenging..